Gammagard Liquid Erc Injection, Solution
Product Images NDC 0944-2705

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Gammagard Liquid Erc (NDC 0944-2705). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Gammagard001)

Illustration depicting a variety of medical supplies arranged on a table, including infusion sets, vials, a syringe, tubing, connectors, alcohol prep pads, gauze, tape, and a medical device likely used for intravenous or subcutaneous administration of medication.*

FDA Label Image

Figure 10 (Gammagard0010)

An illustration showing the proper technique for subcutaneous injection of GAMMAGARD Liquid ERC. It depicts a hand holding a needle at a 90-degree angle to the skin, with an arrow indicating the insertion direction. The image focuses on the abdomen area, demonstrating correct needle placement for intravenous or subcutaneous administration.*

FDA Label Image

Figure 11 (Gammagard0011)

Illustration showing a subcutaneous injection procedure, with a hand securing a syringe and an injection site on the abdomen prepared with an adhesive dressing. The syringe is connected to an infusion line inserted under the skin, demonstrating the administration method for a subcutaneous injection.*

FDA Label Image

Figure 12 (Gammagard0012)

Illustration showing a person receiving an intravenous or subcutaneous infusion using a portable infusion pump attached to the body with two adhesive infusion sites. The pump is held in one hand, while tubing connects the pump to the infusion sites secured on the person's torso.*

FDA Label Image

Figure 13 (Gammagard0013)

An instructional illustration depicting a hand holding a syringe positioned for subcutaneous injection. Below the hand is a cross-sectional diagram of skin layers labeled as skin, subcutaneous layer, and muscle layer, with an arrow indicating the needle's path into the subcutaneous tissue.*

FDA Label Image

Figure 2 (Gammagard002)

An illustration showing a person washing their hands under a running faucet with soap, demonstrating proper hand hygiene technique. Water and soap are visible on the hands and running from the faucet.*

FDA Label Image

Figure 3 (Gammagard003)

An illustration showing a hand holding a vial with a blue cap, likely demonstrating how to open or handle the vial. The image suggests preparation for injection or infusion, consistent with injectable solutions.*

FDA Label Image

Figure 4 (Gammagard004)

An instructional illustration showing a hand peeling back the protective seal from the top of a vial containing a liquid solution. The vial is clear and filled with a blue liquid, suggesting preparation for intravenous or subcutaneous injection.*

FDA Label Image

Figure 5 (Gammagard005)

An illustration showing a person preparing an injection by drawing liquid from a vial into a syringe, demonstrating proper technique for medication administration.*

FDA Label Image

Figure 6 (Gammagard006)

An instructional illustration showing a hand holding a syringe connected to an intravenous line, with the other hand pressing a roller clamp on the tubing to control the flow. The image depicts a step in preparing or administering an intravenous injection.*

FDA Label Image

Figure 7 (Gammagard007)

Illustration showing the recommended injection sites on the human body for GAMMAGARD Liquid ERC (Immune Globulin Infusion). The diagram depicts patch areas on both upper arms and the lower back, indicating possible intravenous and subcutaneous injection locations for the solution.*

FDA Label Image

Figure 8 (Gammagard008)

Illustration showing a human torso from the front with highlighted areas on the lower abdomen and upper thigh, likely indicating preferred sites for subcutaneous administration of GAMMAGARD Liquid ERC injection, a 100 mg/mL immune globulin infusion.*

FDA Label Image

Figure 9 (Gammagard009)

An instructional illustration showing a person preparing an injection site on the abdomen by cleaning the skin with a swab or wipe. The hands are holding a small piece of gauze or alcohol pad against the skin just above the beltline, implying preparation for a subcutaneous injection.*

FDA Label Image

Principal Display Panel (10 mL Bottle Label)

Label for GAMMAGARD Liquid ERC 10% Solution for Infusion, Immune Globulin Infusion (Human), 5 g in 50 mL single-dose vial. The label specifies use for intravenous or subcutaneous administration, refrigeration requirements (2° to 8°C), and that it is not made with natural rubber latex. Manufactured by Takeda Pharmaceuticals America, Inc., Cambridge, MA.*

FDA Label Image

Principal Display Panel (10 mL Bottle Carton)

Packaging label for GAMMAGARD Liquid ERC 10% Solution for Infusion, Immune Globulin Infusion (Human) by Takeda Pharmaceuticals America, Inc. The label indicates a 5 g/50 mL single-dose vial with no preservative and stabilized with glycine. It is for intravenous or subcutaneous administration with refrigeration storage instructions, emphasizing it is made from human plasma and prescription use only.*

FDA Label Image

Principal Display Panel (25 mL Bottle Label)

Label for GAMMAGARD Liquid ERC 10% Solution for Infusion, Immune Globulin Infusion (Human) by Takeda Pharmaceuticals America, Inc. It is a 10 g per 100 mL single-dose vial for intravenous or subcutaneous use. The label includes storage instructions (refrigeration 2° to 8°C, do not freeze, or room temperature up to 25°C), latex-free statement, barcode, and manufacturer address.*

FDA Label Image

Principal Display Panel (25 mL Bottle Carton)

Packaging label for GAMMAGARD Liquid ERC, 10% Solution for Infusion, Immune Globulin Infusion (Human) in a single-dose vial containing 10 g per 100 mL. The label states the product is for intravenous or subcutaneous administration, contains less than or equal to 2 µg/mL IgA, and is distributed by Takeda Pharmaceuticals U.S.A., Inc. It includes storage instructions and trademark information, noting the product is made from human plasma and is labeled as Rx only.*

FDA Label Image

Figure 1 (Gammagard1)

An illustration showing a hand holding a small vial with a blue flip cap partially removed, demonstrating how to prepare or access the contents of the vial. The vial contains a clear liquid. This instructional image is likely related to the preparation of GAMMAGARD Liquid ERC, an Immune Globulin Infusion (Human) injectable solution.*

FDA Label Image

Figure 2 (Gammagard2)

Illustration showing a hand pouring a powder from a small packet into a vial containing a liquid. The vial has a blue liquid and a gray stopper with a clear flip-off cap. This likely demonstrates preparation or mixing of an injectable solution.*

FDA Label Image

Figure 3 (Gammagard3)

An illustration showing a hand holding a vial and drawing liquid into a syringe, demonstrating the preparation of an injection dose. The vial is upside down, connected to the syringe for fluid transfer.*

FDA Label Image

Figure 4 (Gammagard4)

Illustration showing a rear view of a human torso and arms with multiple patch application sites. Patches are positioned on both upper arms and the lower back, demonstrating potential locations for subcutaneous administration.*

FDA Label Image

Figure 5 (Gammagard5)

Illustration showing the recommended injection sites for GAMMAGARD Liquid ERC Immune Globulin Infusion (Human). It depicts the upper back, lower back, and outer thighs as areas for subcutaneous administration of the injection solution.*

FDA Label Image

Figure 6 (Gammagard6)

An instructional illustration showing a person preparing to administer a subcutaneous injection by pinching the abdominal skin. The image highlights the injection site on the lower abdomen above the waistline with the person's hands holding a piece of gauze or cotton.*

FDA Label Image

Figure 7 (Gammagard7)

An instructional illustration showing a technique for subcutaneous injection. The image depicts hands pinching skin at a 90-degree angle, preparing to insert a needle or catheter into the skin, with emphasis on the correct angle for injection.*

FDA Label Image

Figure 8 (Gammagard8)

An instructional illustration showing the preparation or administration of an intravenous or subcutaneous injection using a syringe connected to tubing. The image focuses on a person's abdomen with adhesive bandages, highlighting the injection site and the medical process involved.*

FDA Label Image

Figure 9 (Gammagard9)

An instructional illustration showing a person’s torso with an intravenous infusion system attached. The image depicts two adhesive infusion sites on the abdomen, connected by tubing to an infusion pump held in the person's hand, indicating the setup for intravenous or subcutaneous administration of a medication.*

FDA Label Image

Logo (Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.